UPDATED: Ex-champ Vertex dumps hep C, but shares spike on positive CF results

John Carroll With Gilead's Sovaldi elbowing Vertex's Incivek aside, Vertex is calling it quits on a once-ambitious R&D effort to keep a niche for itself in hepatitis C. ...

Novo, Teva, Shire, Actavis and Mylan post Q1 growth as Endo gets pummeled

Carly Helfand Earnings were kind to many of pharma's midsize players between Wednesday and Thursday, with several drugmakers–Endo excluded–posting growth. But not all ...

Pfizer expansion allows it to make drugs for trials at Cork, Ireland, facility

Eric Palmer Pfizer has opened an expanded product technology laboratory at its Ringaskiddy, County Cork, facility. The company has invested about $ 30 million in the lab, Business ...

VC Lightstone lands $172M with an eye on biotech startups

Damian Garde Lightstone Ventures, the life sciences-focused progeny of two VC stalwarts, has wrapped up a fund of its own, setting out with $ 172 million to back early-stage drug and ...

Biopsy snafu torpedoes PhII prostate cancer data for Nymox

John Carroll A high rate of incorrect biopsies has tangled the mid-stage results for Nymox Pharmaceutical’s experimental prostate cancer drug. Investigators say that NX-1207 reduced ...

Reckitt Benckiser gives up on Merck OTC deal, leaving Bayer open shot

Eric Palmer British consumer goods giant Reckitt Benckiser indicated Wednesday that bidding for the consumer healthcare unit of Merck had gotten out of hand, and so it decided to step ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS